<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-seven patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (20 severe: 7 moderate) were treated with combined immunosuppression consisting of antilymphocyte globulin (ALG: Ahlbulin, Green Cross Co., Osaka, Japan) and high-dose <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="1" ids="4315">Danazol</z:chebi> or meptiostane was administered concurrently for at least 3 months </plain></SENT>
<SENT sid="2" pm="."><plain>Ten of 27 patients had sustained improvement in hematopoiesis within 3 months of treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Three patients with hematological response had a recurrence of <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> 12-36 months after the combined immunosuppressive therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Six patients died due to fungal <z:hpo ids='HP_0002090'>pneumonia</z:hpo> (2), <z:hpo ids='HP_0001399'>hepatic failure</z:hpo> (2), <z:hpo ids='HP_0006515'>interstitial pneumonitis</z:hpo> (1) and complication following allogeneic bone marrow transplantation (1) </plain></SENT>
<SENT sid="5" pm="."><plain>By life table analysis, the survival rate for <z:hpo ids='HP_0000001'>all</z:hpo> patients was 76 +/- 8% at 4 years, with 70 +/- 10% survival rate for patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and 100% for patients with moderate <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The factors predicting the good response to the therapy were a longer interval from diagnosis to the therapy and higher counts of platelet and reticulocyte at admission </plain></SENT>
</text></document>